The effect of bromocriptine on c-reactive protein in women withhyperprolactinemic amenorrhea

الملخص EN

C-reactive protein has become the subject of avid interest in recent years.

Increased concentrations of C-reactive protein (CRP) became widely accepted as a risk factor of many inflammatory diseases including atherosclerosis, ischemic vascular diseases, type 2 diabetes mellitus, hypertension and colon cancer.

Data evaluating the concentration of CRP in hyperprolactinemic condition and the effect of bromocriptine on CRP concentration are not available.

Thus the present study was designed to measure the concentration of CRP in a number of women with hyperprolactinemic amenorrhea and to evaluate the effect of bromocriptine on CRP concentration.

The study tackled sixty women, who had amenorrhea for at least three months and serum prolactin concentration at least twice the upper limit of normal values.

Bromocriptine is administered in a daily dose of 2 (2.5 mg) tablets.

Serum prolactin and serum CRP were assessed before and after bromocriptine administration, using commercial kits.

Mean CRP concentration of the control group was 1.38 ± 1.85 mg / L which is statistically lower than value of 6.35 ± 4.62 mg / L of the patients before bromocripine therapy (P<0.001).

A significant drop of CRP (from a mean of 6.35 ± 4.62 mg / L to a mean of 2.73 ± 3.14 mg / L) was obtained after treatment with bromocriptine (P<0.001).

The correlation between serum prolactin level and serum CRP level before and after bromocriptine administration was not statistically significant : r = 0.24, P>0.05 and r = 0.12, P>0.2, respectively.

The present study showed that women with hyperprolactinemic amenorrhea is associated with increased level of CRP and therapy with bromocriptine significantly reduced CRP, suggesting a possible anti-inflammatory action of bromocriptine in addition to prolactin lowering effects.